Early Diagnosis of Gastric Cancer Cachexia

Cachexia Clinical Trial

Official title:

Clinical Value of Tumor Cell-derived Exosomal miRNA in Early Diagnosis of Gastric Cancer Cachexia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06277986
• Other study ID #: KY20212018-F-2
• Status: Recruiting
• Start date: June 1, 2021
• Est. completion date: September 1, 2024

Study information

• Verified date: January 2024
• Source: Xijing Hospital
• Contact: Jipeng Li
• Phone: +86-029-84771533
• Email: jiangxunliang1992[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Description:

Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In gastric cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with gastric cancer diagnosed by histopathology or cytopathology

2. Complete clinical and pathological data

3. No previous or current mental illness or disturbance of consciousness

Exclusion Criteria:

1. With multiple tumors or other malignant diseases

2. Combined with other chronic wasting and metabolic diseases

3. Past patients with non-tumor cachexia

4. People with mental illness or unable to cooperate

Related Conditions & MeSH terms

• Cachexia

Intervention

Other:
• cachexia
Cachexia mainly manifests as weight loss. 1)weight loss >5% over past 6 months. 2)BMI<20 and any degree of weight loss >2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss >2%.

Locations

Country	Name	City	State
China	Fourth Military Medical University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BMI	Calculate BMI based on changes in body weight in the past six months	six months